Furui Co.,Ltd(SZ:300049)2022-12-07 09:08Group 1: Company Transformation and Structure - In 2015, the company is undergoing a transformation towards medical services, focusing on several key areas including the establishment of 100 health management centers for liver disease [2][3]. - The company has restructured its operations, creating a pharmaceutical subsidiary in Jining, focusing on GMP and hospital formulations, while sales operations are centralized in Hohhot [2][3]. - The French subsidiary Echosens is responsible for medical diagnostic technology research and sales of medical devices [2][3]. Group 2: Financial Insights and Revenue Streams - A liver disease patient typically spends over 10,000 yuan annually on medication [3]. - The company aims to gradually increase the proportion of service revenue to a reasonable level, while maintaining stable growth in traditional pharmaceutical and instrument sales [4]. - The company has over 40 types of liver disease medications available for the health management centers [4]. Group 3: Development Plans and Collaborations - The company plans to enhance its online chronic liver management services and expand its range of liver disease medications [3]. - Collaboration with hospitals to establish health management centers is a priority, with each prefecture-level city targeted to have one center [4]. - The company provides advanced diagnostic tools like Fibroscan to partner hospitals, enhancing their academic image and reducing equipment investment [4]. Group 4: Management and Governance - The governance structure of Echosens will be improved to align with the company's strategic goals of becoming a leader in the global liver disease diagnostics industry [3]. - The management team regularly reports significant matters to ensure alignment with the company's objectives [3].